Plasmagen Biosciences taps into niche Indian biopharma market with launch of CSL’s Haemocomplettan®P
Haemocomplettan® P will cater to the 1,50,000 cardiac surgeries and over 1,800 liver transplant patients who are at risk of massive bleeding due to acquired hypofibrinogenemia